image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 36.99
2.21 %
$ 2.21 B
Market Cap
-10.94
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TWST stock under the worst case scenario is HIDDEN Compared to the current market price of 37 USD, Twist Bioscience Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TWST stock under the base case scenario is HIDDEN Compared to the current market price of 37 USD, Twist Bioscience Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TWST stock under the best case scenario is HIDDEN Compared to the current market price of 37 USD, Twist Bioscience Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TWST

image
$56.0$56.0$54.0$54.0$52.0$52.0$50.0$50.0$48.0$48.0$46.0$46.0$44.0$44.0$42.0$42.0$40.0$40.0$38.0$38.0$36.0$36.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
313 M REVENUE
27.69%
-221 M OPERATING INCOME
-1.69%
-209 M NET INCOME
-2.01%
-64.1 M OPERATING CASH FLOW
55.01%
-3.07 M INVESTING CASH FLOW
-6.07%
6.89 M FINANCING CASH FLOW
656.31%
88.7 M REVENUE
4.73%
-34.6 M OPERATING INCOME
3.88%
-31.6 M NET INCOME
8.83%
-21.4 M OPERATING CASH FLOW
-39.87%
-1.54 M INVESTING CASH FLOW
-19.53%
17.9 M FINANCING CASH FLOW
394.73%
Balance Sheet Twist Bioscience Corporation
image
Current Assets 347 M
Cash & Short-Term Investments 276 M
Receivables 34.9 M
Other Current Assets 35.5 M
Non-Current Assets 268 M
Long-Term Investments 0
PP&E 161 M
Other Non-Current Assets 106 M
44.99 %5.68 %5.77 %26.26 %17.29 %Total Assets$614.3m
Current Liabilities 71 M
Accounts Payable 1.63 M
Short-Term Debt 29.6 M
Other Current Liabilities 39.8 M
Non-Current Liabilities 70.6 M
Long-Term Debt 70.2 M
Other Non-Current Liabilities 407 K
20.91 %28.08 %49.58 %Total Liabilities$141.6m
EFFICIENCY
Earnings Waterfall Twist Bioscience Corporation
image
Revenue 313 M
Cost Of Revenue 180 M
Gross Profit 133 M
Operating Expenses 354 M
Operating Income -221 M
Other Expenses -12.1 M
Net Income -209 M
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)313m(180m)133m(354m)(221m)12m(209m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
42.61% GROSS MARGIN
42.61%
-70.56% OPERATING MARGIN
-70.56%
-66.69% NET MARGIN
-66.69%
-44.16% ROE
-44.16%
-33.98% ROA
-33.98%
-38.65% ROIC
-38.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Twist Bioscience Corporation
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -209 M
Depreciation & Amortization 31.4 M
Capital Expenditures -5.08 M
Stock-Based Compensation 50.9 M
Change in Working Capital 15.4 M
Others 57.6 M
Free Cash Flow -69.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Twist Bioscience Corporation
image
Wall Street analysts predict an average 1-year price target for TWST of $50.2 , with forecasts ranging from a low of $40 to a high of $58 .
TWST Lowest Price Target Wall Street Target
40 USD 8.14%
TWST Average Price Target Wall Street Target
50.2 USD 35.62%
TWST Highest Price Target Wall Street Target
58 USD 56.80%
Price
Max Price Target
Min Price Target
Average Price Target
6060555550504545404035353030May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Twist Bioscience Corporation
image
Sold
0-3 MONTHS
1.42 M USD 7
3-6 MONTHS
4.24 M USD 7
6-9 MONTHS
2.02 M USD 6
9-12 MONTHS
991 K USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate the adoption of NGS workflows in agricultural genomics (agrigenomics) by offering Twist's FlexPrep™ Ultra-High Throughput (UHT) Library Preparation Kit with Curio's bioinformatics software. businesswire.com - 2 weeks ago
Promising Genomics & Synthetic Biology Stocks to Consider in 2025 Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG. zacks.com - 2 weeks ago
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last? Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 1 month ago
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. “At Twist, we recognize the increasing challenge within colleges, universities and research ins. businesswire.com - 1 month ago
Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 months ago
Cathie Wood dumped Palantir to buy these biotech stocks Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure. finbold.com - 2 months ago
Twist Bioscience: Valuation Is Weighing On The Stock Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future. seekingalpha.com - 2 months ago
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Sung-Ji Nam - Scotiabank Operator Good day. Thank you for standing by. seekingalpha.com - 2 months ago
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago. zacks.com - 2 months ago
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report. businesswire.com - 2 months ago
Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033). The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033). globenewswire.com - 2 months ago
All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
8. Profile Summary

Twist Bioscience Corporation TWST

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 2.21 B
Dividend Yield 0.00%
Description Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Contact 681 Gateway Boulevard, South San Francisco, CA, 94080 https://www.twistbioscience.com
IPO Date Oct. 31, 2018
Employees 923
Officers Dr. Michael Fero Ph.D. Chief Information Officer Dr. Emily Marine Leproust Ph.D. Co-Founder, Board Chair & Chief Executive Officer Mr. Siyuan Chen Chief Technology Officer Dr. Patrick John Finn Ph.D. President & Chief Operating Officer Dr. William Charles Banyai Ph.D. Senior Vice President of Advanced Development, GM of Data Storage & Director Mr. Dennis Cho J.D. Senior Vice President, Chief Legal Officer & Corporate Secretary Mr. Robert F. Werner Vice President & Chief Accounting Officer Ms. Nicole Moreno Senior Vice President of Sales & Support Ms. Paula Green Senior Vice President of Human Resources Mr. Adam Laponis Chief Financial Officer